Bharat Parenterals Ltd

Net Loss of Bharat Parenterals reported to Rs 4.80 crore in the quarter ended March 2026 as against net loss of Rs 4.73 crore during the previous quarter ended March 2025. Sales declined 4.19% to Rs 99.62 crore in the quarter ended March 2026 as against Rs 103.98 crore during the previous quarter ended March 2025. For the full year,net loss reported to Rs 8.19 crore in the year ended March 2026 as against net loss of Rs 12.63 crore during the previous year ended March 2025. Sales rose 1.48% to Rs 345.43 crore in the year ended March 2026 as against Rs 340.38 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales99.62103.98 -4 345.43340.38 1 OPM %-0.532.14 -4.580.79 - PBDT0.260.22 18 12.831.37 836 PBT-8.37-8.30 -1 -21.42-33.95 37 NP-4.80-4.73 -1 -8.19-12.63 35 Powered by Capital Market - Live

Bharat Parenterals announced that the Board of Directors of the Company at its meeting held on 18 May 2026, has recommended a Final Dividend of Rs.1 per share (i.e.10%), subject to the approval of the shareholders.

Bharat Parenterals will hold a meeting of the Board of Directors of the Company on 18 May 2026.

The inspection of the General Injectables Block was carried out from 13 April to 17 April 2026 and concluded on 20 April 2026. At the conclusion of the inspection, the USFDA issued five observations under a Voluntary Action Indicated (VAI) classification. The company said its subsidiary will respond within the prescribed timeline, while the final Establishment Inspection Report (EIR) is awaited. The General Injectables Block is a key facility that supports the supply of sterile injectable formulations to regulated markets, including the United States and the European Union. Commenting on the development, the company's management said, 'A surprise USFDA inspection of a sterile injectables block, concluding with a few procedural observations under a VAI classification, reflects the consistency of quality and compliance systems at Innoxel. The company continues to focus on strengthening its manufacturing and regulatory capabilities.' Bharat Parenterals as a pharmaceutical company. The Company develops anti-retroviral drugs in the form of tablets, capsules, oral liquids, eye drops, lotion, creams, and injections for the treatment of various diseases. Bharat Parenterals serves clients in India. The company reported consolidated net loss of Rs 4.39 crore in Q3 FY26 as against net loss of Rs 1.67 crore in the same quarter last year. Revenue from operations fell 9.8% YoY to Rs 65.19 crore in the quarter ended 31 December 2026. The counter added 1.31% to Rs 1,201.25 on the BSE.

Net Loss of Bharat Parenterals reported to Rs 4.39 crore in the quarter ended December 2025 as against net loss of Rs 1.67 crore during the previous quarter ended December 2024. Sales declined 9.78% to Rs 65.19 crore in the quarter ended December 2025 as against Rs 72.26 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales65.1972.26 -10 OPM %2.675.04 - PBDT0.173.25 -95 PBT-8.28-5.50 -51 NP-4.39-1.67 -163 Powered by Capital Market - Live

Bharat Parenterals will hold a meeting of the Board of Directors of the Company on 30 January 2026.Powered by Capital Market - Live

Net Loss of Bharat Parenterals reported to Rs 7.24 crore in the quarter ended September 2025 as against net loss of Rs 7.50 crore during the previous quarter ended September 2024. Sales declined 9.79% to Rs 64.62 crore in the quarter ended September 2025 as against Rs 71.63 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales64.6271.63 -10 OPM %1.28-10.69 - PBDT1.25-6.36 LP PBT-7.31-15.37 52 NP-7.24-7.50 3 Powered by Capital Market - Live

Bharat Parenterals will hold a meeting of the Board of Directors of the Company on 12 November 2025.Powered by Capital Market - Live

Bharat Parenterals announced that the Annual General Meeting(AGM) of the company will be held on 26 September 2025.Powered by Capital Market - Live

Bharat Parenterals announced that its subsidiary, Innoxel Lifesciences, has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its finished dosage manufacturing facility in Vadodara, Gujarat. This follows the successful completion of the U.S. FDA inspection conducted from April 28 to May 2, 2025. The facility is capable of manufacturing, packaging, testing, storage and distribution of two types of complex dosage forms - Liquid Injectables and Oral Liquids. With the receipt of the EIR, Innoxel Lifesciences has also received acceptance of the site for commercial operations for the product(s) under inspection. This milestone reinforces Innoxel's commitment to global quality benchmarks and enhances its capability to supply high-quality pharmaceutical products to regulated markets, such as United States and the European Union.Powered by Capital Market - Live